(firstQuint)A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis (UC) Korean Participants.

 This is a retrospective, non-interventional study of participants with moderate to severe UC.

 The study will review medical records of participants who have initiated medical treatment with vedolizumab intravenous during the defined eligibility period under routine clinical practice to provide the real world data on the effectiveness and safety of vedolizumab intravenous.

 The study will enroll approximately 100 participants.

 All participants will be enrolled in one observational group: Vedolizumab The retrospective data will be collected in the index period, that is the time between 01 August 2017 and 30 June 2018, from the date of diagnosis of UC until the date when participant is enrolled into the study on Baseline or until the end of treatment or death of participants or lost-to-follow up.

 The multi-center trial will be conducted in Republic of Korea.

 The overall duration of study will be approximately 12 months.

.

 A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis (UC) Korean Participants@highlight

The purpose of this study is to assess the clinical effectiveness by the clinical response at 6 weeks and the safety of vedolizumab intravenous in UC Korean participants.

